Skip to main content

Advertisement

SpringerLink
Log in

Imbalance and Gait Disturbance from Tyrosine Kinase Inhibition in Hepatocellular Cancer

  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Zhu AX, Sahani DV, Duda D, et al. Efficacy, safety and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27(18):3027–35.

    Article  CAS  PubMed  Google Scholar 

  2. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–37.

    CAS  PubMed  Google Scholar 

  3. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Molecular cancer therapeutics. 2003;2(5):471–8.

    CAS  PubMed  Google Scholar 

  4. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101(9):3597–605.

    Article  PubMed  Google Scholar 

  5. Sutent Full Prescribing Information. US Food and Drug Administration 2007

  6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  7. Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol. 2007;25(23):3559.

    Article  PubMed  Google Scholar 

  8. Cumurciuc R, Martinez-Almoyna L, Henry C, Husson H, de Broucker T. Posterior reversible encephalopathy syndrome during sunitinib therapy. Revue neurologique. 2008;164(6–7):605–7.

    Article  CAS  PubMed  Google Scholar 

  9. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43–9006. J Clin Oncol. 2006;24(28):e48.

    Article  PubMed  Google Scholar 

  10. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500.

    Article  CAS  PubMed  Google Scholar 

  11. Saito B, Nakamaki T, Nakashima H, et al. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol. 2007;82(4):304–6.

    Article  PubMed  Google Scholar 

  12. van der Veldt AA, van den Eertwegh AJ, Hoekman K, Barkhof F, Boven E. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol. 2007;18(10):1747–50.

    Article  PubMed  Google Scholar 

  13. Patyna S, Peng G. Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intrvenous administration in rodents and monkeys. Eur J Cancer. 2006;4(12):21.

    Google Scholar 

  14. Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP. Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res. 2007;27(6C):4255–7.

    CAS  PubMed  Google Scholar 

  15. Medioni J, Cojocarasu O, Belcaceres JL, Halimi P, Oudard S. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol. 2007;18(7):1282–3.

    Article  CAS  PubMed  Google Scholar 

  16. Negrier S. Case Report 3. Sunitinib malate in patients with cerebellar metastases. Eur J Cancer Suppl. 2007;5(7):32–4.

    Article  CAS  Google Scholar 

  17. Thibault F, Billemont B, Rixe O. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy. J Neurooncol. 2008;86(2):243–4.

    Article  PubMed  Google Scholar 

  18. Helgason HH, Mallo HA, Droogendijk H, et al. Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol. 2008;26(1):152–4.

    Article  PubMed  Google Scholar 

  19. Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol. 2008;53(2):376–81.

    Article  CAS  PubMed  Google Scholar 

  20. Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest. 2000;106(7):829–38.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Beth Israel Deaconess Medical Center, Shapiro 9, Boston, MA, 02215, USA

    Rebecca A. Miksad, Kuan-Chi Lai & Megan E. Healy

  2. Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Marion C. Stein

  3. Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Rafael Rojas & Katherine M. Krajewski

  4. Division of Oncology, Massachusetts General Hospital, Boston, MA, USA

    Andrew X. Zhu

Authors
  1. Rebecca A. Miksad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kuan-Chi Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marion C. Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Megan E. Healy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rafael Rojas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katherine M. Krajewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrew X. Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rebecca A. Miksad.

Additional information

The patient descried in this manuscript was enrolled on a phase II trial supported by Pfizer, as reported in Zhu et al., J Clin Oncol 27:3027–3035. This manuscript reports distinct and unique clinical and imaging information about an individual patient that has not been reported or presented previously.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miksad, R.A., Lai, KC., Stein, M.C. et al. Imbalance and Gait Disturbance from Tyrosine Kinase Inhibition in Hepatocellular Cancer. J Gastrointest Canc 40, 119–122 (2009). https://doi.org/10.1007/s12029-009-9086-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-009-9086-7

Keywords

Search

Navigation